Tirzepatide Pharma Peptide Synthesis Technology 

 

Tirzepatide Pharma's ongoing research on the bioavailability of orally administered peptides compared to the subcutaneous route shows that 1 mg of peptide administered sublingually daily is equivalent to 5 mg administered subcutaneously weekly. The research aims to suggest alternative methods for alleviating injection site redness, pain, swelling, and total body chills, as well as muscular pain, triggered by subcutaneous administration in approximately 20% of the population.

Their sublingual peptide lozenges come in various forms, shapes, and sizes, ranging from mini capsules to tabs, each enhanced with 3mg Sodium salcaprozate (SNAC) to improve absorption. Sublingual administration was said to be comparable to subcutaneous administration, as neither undergoes enzymatic degradation by gastric acid, and they offer the sublingual peptide for research purposes only.

Tirzepatide Pharma is an FDA-registered API Peptide and monograph drug facility offering in-house Solid-Phase Peptide Synthesis utilizing cutting-edge peptide synthesizers, analytical-preparatory HPLC, and PEP Easy Clean purification technology for the highest purity. Provides pre-clinical investors with peptides for investigational drug trials. All peptides are Bachem-retested for purity, sequencing, amino acid identification, and mapping.

 

Our mission as a peptide pharmacology company is to discover modifications in the nucleotide structure that effectively modify the human genome, thereby elongating telomeres to enhance longevity and increase the average human lifespan to 140 years, while maintaining the youthful internal organs that sustain life.